Does Resistance to Pyrazinamide Accurately Indicate the Presence of Mycobacterium bovis ?
Open Access
- 1 July 2005
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (7) , 3530-3532
- https://doi.org/10.1128/jcm.43.7.3530-3532.2005
Abstract
Mycobacterium bovis is best identified by screening those isolates of the Mycobacterium tuberculosis complex that have any pyrazinamide (PZA) resistance, using a confirmatory test such as spoligotyping, biochemical testing, or genomic deletion analysis. The sensitivity for detection of M. bovis is lowered to 82% when only PZA-monoresistant isolates are screened.Keywords
This publication has 11 references indexed in Scilit:
- Epidemiology of Mycobacterium bovis disease in San Diego County, 1994-2000.2003
- A new evolutionary scenario for the Mycobacterium tuberculosis complexProceedings of the National Academy of Sciences, 2002
- Pyrazinamide-Monoresistant Mycobacterium tuberculosis in the United StatesJournal of Clinical Microbiology, 2001
- Use of multiple markers in population-based molecular epidemiologic studies of tuberculosis.2000
- A Molecular Epidemiologic Analysis of Tuberculosis Trends in San Francisco, 1991–1997Annals of Internal Medicine, 1999
- Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiologyJournal of Clinical Microbiology, 1997
- Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosisJournal of Clinical Microbiology, 1996
- Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodologyJournal of Clinical Microbiology, 1993